Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions

2024-513753-75-00 Protocol BLCL-AMC-03 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 12 Aug 2024 · End 17 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BLCL-AMC-03

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 32
Countries 1
Sites 1

No medical condition.

Key facts

Sponsor
Bial Portela & Ca S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
12 Aug 2024 → 17 Sep 2024
Decision date (initial)
2024-07-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No medical condition.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bial Portela & Ca S.A.

Sponsor organisation
Bial Portela & Ca S.A.
Address
A Avenida Da Siderurgia Nacional
City
Sao Mamede Do Coronado
Postcode
4745-457
Country
Portugal

Scientific contact point

Organisation
Bial Portela & Ca S.A.
Contact name
Andreia Guimarães

Public contact point

Organisation
Bial Portela & Ca S.A.
Contact name
Andreia Guimarães

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 32 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, Rua De Sarmento De Beires 153 0 Floor 3rd Floor, 4250-449, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2024-08-12 2024-09-17 2024-08-12 2024-08-19

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-14 Portugal Acceptable
2024-07-06
2024-07-11
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-21 Portugal Acceptable
2024-09-16
2024-09-17
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-17 Portugal Acceptable
2024-09-16
2024-09-17